Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Orforglipron, developed by Eli Lilly, is the first non-peptide oral GLP-1 agonist, achieving up to 1.8% HbA1c reduction and 1012% body-weight loss in Phase 3 trials
Advanced / Aggressive Approach (2 mL = ~5,000 mcg/mL) Reconstitute: Add 2.0 mL bacteriostatic water to one 10 mg vial final concentration: ~5,000 mcg/mL
Taylor starts low, goes slow, and adjusts your plan to keep you comfortable
The company highlights thousands of unique formulations and a large team of technical staff dedicated to research, development, and quality control
Intramuscular injection is technically more demanding and carries greater risk than the subcutaneous route, so it should only be undertaken with proper training and a clear anatomical understanding of the chosen site
When used with insulin or sulfonylureas, these medications may increase hypoglycemia risk, requiring dose adjustments of those agents
US$ 21.82
US$ 25.33
US$ 20.44
US$ 24.24
US$ 26.30
US$ 26.50
US$ 29.77
